
Cinven buys Amdipharm for £367m
Cinven has acquired UK-based pharmaceuticals business Amdipharm Group for £367m.
Cinven intends to merge the Amdipharm Group with its current portfolio company Mercury Pharma, a speciality pharmaceutical firm the GP acquired in August this year, to create a global business. The Amdipharm Group will operate as a stand-alone entity until the merger.
The firm's founders, who owned the business prior to the sale, will retain a significant minority stake in the combined company.
Company
Founded in 2002 and based in Basildon, the Amdipharm Group markets speciality branded or unbranded pharmaceuticals. The firm has made 18 acquisitions to expand its portfolio of products, which now exceeds 50, and has offices in Jersey, Ireland, the Netherlands and Essex.
The company retails in more than 80 countries and generates revenues of more than £110m.
People
Supraj Rajagopalan is a partner at Cinven.
Advisers
Equity – Jefferies (Corporate finance).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater